Stiewe T - Search Results

1

Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.

Pavlakis E, Neumann M, Merle N, Wieboldt R, Wanzel M, Ponath V, Pogge von Strandmann E, Elmshäuser S, Stiewe T. Pavlakis E, et al. Among authors: stiewe t. J Exp Clin Cancer Res. 2023 Aug 10;42(1):203. doi: 10.1186/s13046-023-02785-z. J Exp Clin Cancer Res. 2023. PMID: 37563605 Free PMC article.

2

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.

Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling A, Rödel F, Weber K, Fehse B, Mack E, Stiewe T, Doerr HW, Speidel D, Cinatl J Jr. Michaelis M, et al. Among authors: stiewe t. Cell Death Dis. 2011 Dec 15;2(12):e243. doi: 10.1038/cddis.2011.129. Cell Death Dis. 2011. PMID: 22170099 Free PMC article.

3

Identification of the full-length huntingtin- interacting protein p231HBP/HYPB as a DNA-binding factor.

Rega S, Stiewe T, Chang DI, Pollmeier B, Esche H, Bardenheuer W, Marquitan G, Pützer BM. Rega S, et al. Among authors: stiewe t. Mol Cell Neurosci. 2001 Jul;18(1):68-79. doi: 10.1006/mcne.2001.1004. Mol Cell Neurosci. 2001. PMID: 11461154

4

KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment.

Schön M, Wienrich BG, Kneitz S, Sennefelder H, Amschler K, Vöhringer V, Weber O, Stiewe T, Ziegelbauer K, Schön MP. Schön M, et al. Among authors: stiewe t. J Natl Cancer Inst. 2008 Jun 18;100(12):862-75. doi: 10.1093/jnci/djn174. Epub 2008 Jun 10. J Natl Cancer Inst. 2008. PMID: 18544741

5

A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism.

Pribluda A, Elyada E, Wiener Z, Hamza H, Goldstein RE, Biton M, Burstain I, Morgenstern Y, Brachya G, Billauer H, Biton S, Snir-Alkalay I, Vucic D, Schlereth K, Mernberger M, Stiewe T, Oren M, Alitalo K, Pikarsky E, Ben-Neriah Y. Pribluda A, et al. Among authors: stiewe t. Cancer Cell. 2013 Aug 12;24(2):242-56. doi: 10.1016/j.ccr.2013.06.005. Epub 2013 Jul 25. Cancer Cell. 2013. PMID: 23890787 Free article.

6

Regulation of telomerase activity by the p53 family member p73.

Beitzinger M, Oswald C, Beinoraviciute-Kellner R, Stiewe T. Beitzinger M, et al. Among authors: stiewe t. Oncogene. 2006 Feb 9;25(6):813-26. doi: 10.1038/sj.onc.1209125. Oncogene. 2006. PMID: 16205639

7

p73 in apoptosis.

Stiewe T, Pützer BM. Stiewe T, et al. Apoptosis. 2001 Dec;6(6):447-52. doi: 10.1023/a:1012433522902. Apoptosis. 2001. PMID: 11595834 Review.

8

Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73.

Stiewe T, Stanelle J, Theseling CC, Pollmeier B, Beitzinger M, Pützer BM. Stiewe T, et al. J Biol Chem. 2003 Apr 18;278(16):14230-6. doi: 10.1074/jbc.M300357200. Epub 2003 Feb 12. J Biol Chem. 2003. PMID: 12584188 Free article.

9

Role of p73 in malignancy: tumor suppressor or oncogene?

Stiewe T, Pützer BM. Stiewe T, et al. Cell Death Differ. 2002 Mar;9(3):237-45. doi: 10.1038/sj.cdd.4400995. Cell Death Differ. 2002. PMID: 11859406 Review.

10

Increased DeltaN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promoter-derived DeltaN'-p73 transcript.

Pützer BM, Tuve S, Tannapfel A, Stiewe T. Pützer BM, et al. Among authors: stiewe t. Cell Death Differ. 2003 May;10(5):612-4. doi: 10.1038/sj.cdd.4401205. Cell Death Differ. 2003. PMID: 12728260 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

164 results

Search Page

Filters